Corporate Workshop
Aventa FusionPlus: The 3D Genomics Solution to Diagnostic Dilemmas in Solid Tumors
Wednesday, November 20th, 2024 | 3:00 pm – 3:50 pm PST
Location: 221 & 222, Level 2
In this workshop, explore the groundbreaking application of 3D genomics in tumor diagnostics and therapeutic selection. Discover how 3D genomics identifies clinically actionable fusions and complex structural rearrangements that traditional methods miss. Learn how the Aventa FusionPlus test can be used to:
• Double the detection rate of gene fusions (NTRK, ROS1, EGFR, RET, ALK) in patients who may be eligible for targeted therapies
• Increase the detection rate of deleterious HRR mutations in patients who may be eligible for PARP inhibitors
• Resolve diagnostic dilemmas in translocation-driven tumors
Save Your Seat
Meet the Speakers
Anthony Schmitt, PhD
SVP of Science, Arima GenomicsAnthony Schmitt, PhD, has led the development of the core Arima Hi-C chemistry and technology platform since Arima’s inception, contributed to core inventions and technology development grants, and continues to lead the R&D programs for targeted chromosome conformation capture techniques.
Anthony M. Magliocco, MD
Protean BiodiagnosticsDr. Anthony Magliocco is a board-certified pathologist and professor of oncology and pathology with over 30 years of experience in precision medicine and cancer diagnostics. As the founder and CEO of Protean BioDiagnostics, he leads efforts to accelerate the deployment of precision oncology to underserved cancer patients. With over 200 published research articles and numerous patents, Dr. Magliocco has made significant contributions to the field of precision oncology.